Metly automates the manual work behind your teams' most important decisions, inside the tools they already use.
Our team comes from
Pharma spent two decades building systems to hold its data. Veeva, Salesforce, IQVIA, Cortellis. The data is there. It lives in silos, changes every day, and sits far from the decisions it should inform.
Analysts spend weeks piecing together data by hand. Teams duplicate each other's work across regions. Everyone reacts late.
It is the missed windows. Strategic openings close while the slide deck is still being built.
Metly is the connective layer underneath your commercial stack. It unifies fragmented internal and external data into a context engine that AI agents can reason over, and gives those agents secure rails to execute across the software you already run.
Internal files, CRM, SharePoint, market feeds, trial registries, regulatory databases. One graph, kept current.
Agents understand your entities, your policies and your strategy, so they know what a competitor readout means for your portfolio, not just that it happened.
Event-driven loops run in the background and update the documents, models and systems your teams work in. You review. You do not rebuild.
Every pharma company is building AI in-house right now. We are built to make that work. Our engineers and pharma experts embed with your business units, learn how your company actually decides, and encode it into Metly, alongside your own teams and the partners you already trust. What you get adapts to you, and stays yours.
Metly puts the three together, so agents work inside your business rather than advise from outside it. Context tells them what a signal means for you. Your rules tell them how to act on it. Execution lets them do it, through the systems you already use, with the right person in the loop.
Molecules, indications, trials, regulatory events, payers, competitors, territories. All linked and kept current. Metly runs where your company already runs, on your cloud, in your tenancy, or alongside your existing systems. Agents start from what your company already knows, and your data stays where it is.
Our forward-deployed team sits with your team. Metly then learns how decisions actually get made, and builds those rules into every agent. They are written down, testable and easy to change when your process changes.
Secure rails into the documents and systems of record your teams already use. Agents show their work: every action sourced and logged. Anything that needs sign-off goes to the right person before it lands.
Metly sits between your data and your work. It reads every source your teams rely on, understands what a change means for your products and markets, and writes the result back into the documents and systems where decisions are made.
5 commercial-side departments, 10 functions where Metly runs today. Pick one to see what changes.
The manual work between your data and your decisions. Pharma teams spend weeks pulling signals from internal files, market feeds and expert notes, and rebuilding the same decks, forecasts and briefs every cycle. Metly connects those sources into one context, applies your rules, and keeps the outputs current inside the tools your teams already use, so the work that used to take weeks is already done when the decision comes.
Metly works with the systems you already have rather than replacing them. Wherever you are in your AI journey, the gap is the same: the data lives in silos and the work between them is still done by hand. Metly brings those silos together, encodes how your company decides, and automates the manual work behind your decisions. For companies building in-house, Metly runs in your own environment and connects to what your teams have already built.
From the first conversation. Every engagement starts with a demo built around your specific therapeutic area and team, so you can see exactly what Metly delivers before committing to anything.
Yes. Your internal data is never used to train models or shared across clients. We follow enterprise-grade security standards.
Our team brings hands-on experience from Pfizer, Roche, Novartis, AstraZeneca, J&J, Sanofi, Merck, GSK, Eli Lilly, BMS, AbbVie, Bayer, Takeda, and Boehringer - across oncology, rare disease, CNS, immunology, cardiovascular, and more.
Yes. For biotech companies, Metly helps with asset diligence, competitive landscape analysis, and market positioning - giving you the intelligence you need to understand where your asset fits, who your competitors are, and how to present your story persuasively when engaging with potential pharma partners.
Supported by
